Search
Alnylam Pharmaceuticals Inc
ALNYAdd to Watchlist
205.420USD
-81.200-28.33%
Close 07-29 16:00（ET）Quotes delayed by 15 min
27.19BMarket Cap
50.28P/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
Other
286.75M
7.72%
By RegionUSD
Name
Revenue
Proportion
United States
2.07B
55.67%
Europe
651.09M
17.53%
Net revenues from collaborations
553.37M
14.90%
Rest of World
267.93M
7.21%
Royalty revenue
174.02M
4.69%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
Other
286.75M
7.72%